Get the Stockscreener App
18.76
4.43%
-0.87
After Hours:
18.76
Castle Biosciences Inc stock is traded at $18.76, with a volume of 405.45K.
It is down -4.43% in the last 24 hours and down -32.05% over the past month.
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME, among others. The company's test portfolio consists of test offerings to aid clinicians in the diagnosis and treatment of cancers or precancerous diagnoses in the fields of dermatology, gastroenterology, and ophthalmology and a pharmacogenomics ("PGx") test to guide optimal drug treatment for patients diagnosed with depression, anxiety, and other mental health conditions.
See More
Previous Close:
$19.63
Open:
$19.53
24h Volume:
405.45K
Relative Volume:
0.99
Market Cap:
$534.92M
Revenue:
$219.79M
Net Income/Loss:
$-57.47M
P/E Ratio:
-8.7256
EPS:
-2.15
Net Cash Flow:
$-19.25M
1W Performance:
-8.89%
1M Performance:
-32.05%
6M Performance:
-39.83%
1Y Performance:
-5.54%
1-Day Range:
$18.74
$19.91
1-Week Range:
$18.70
$20.91
52-Week Range:
$16.96
$35.84
Castle Biosciences Inc Stock (CSTL) Company Profile
Name
Castle Biosciences Inc
Sector
Industry
Phone
866-788-9007
Address
505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX
Compare CSTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
18.76 | 534.92M | 219.79M | -57.47M | -19.25M | -2.15 |
|
TMO
Thermo Fisher Scientific Inc
|
508.90 | 191.99B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
204.09 | 145.87B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
117.33 | 33.47B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IDXX
Idexx Laboratories Inc
|
406.29 | 33.04B | 3.90B | 887.87M | 798.08M | 10.67 |
|
IQV
Iqvia Holdings Inc
|
181.43 | 31.99B | 15.41B | 1.37B | 2.11B | 7.50 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Apr-30-21 | Initiated | Lake Street | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Dec-27-19 | Reiterated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | BTIG Research | Buy |
| Aug-19-19 | Initiated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | Robert W. Baird | Outperform |
| Aug-19-19 | Initiated | SVB Leerink | Outperform |
View All
Castle Biosciences Inc Stock (CSTL) Latest News
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Castle Biosciences CEO Derek Maetzold sells $585,673 in stock - Investing.com India
Major Breakthrough: 10,000-Patient Study Proves Castle's Skin Cancer Tests Save Lives - StockTitan
Castle Biosciences Inc to Host Earnings Call - ACCESS Newswire
Solid Earnings Reflect Castle Biosciences' (NASDAQ:CSTL) Strength As A Business - Yahoo Finance
Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Sold by Rhumbline Advisers - Defense World
CSTL Gears Up to Report Q4 Earnings: Here's What You Should Know - MSN
Castle Biosciences, Inc. (NASDAQ:CSTL) Stock Position Boosted by Truist Financial Corp - Defense World
Leerink Partnrs Weighs in on CSTL Q1 Earnings - Defense World
Castle Biosciences (NASDAQ:CSTL) Price Target Raised to $37.00 - Defense World
Castle Biosciences (NASDAQ:CSTL) Shares Gap Up Following Analyst Upgrade - Defense World
What Is Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Doing? - Yahoo Finance
Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Beat Estimates - MSN
Castle Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Castle Biosciences: Strong Growth Potential and Robust Performance Justify Buy Rating - TipRanks
Castle Biosciences, Inc. (NASDAQ:CSTL) Q4 2024 Earnings Call Transcript - Insider Monkey
Q4 2024 Castle Biosciences Inc Earnings Call - Cbainfo
Castle Biosciences Inc (CSTL) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Castle Biosciences Reports Strong 2024 Financial Results - TipRanks
Castle Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Castle Biosciences, Inc. (CSTL) Surpasses Q4 Earnings and Revenue Estimates - MSN
Earnings call transcript: Castle Biosciences Q4 2024 sees strong earnings beat - Investing.com
Castle Biosciences Reports Strong 2024 Financial Performance - TipRanks
How Did Castle Biosciences Transform a $57.5M Loss Into $18.2M Profit? 2024 Results Reveal the Answer - StockTitan
What To Expect From Castle Biosciences Inc (CSTL) Q4 2024 Earnin - GuruFocus.com
What To Expect From Castle Biosciences Inc (CSTL) Q4 2024 Earnings - Yahoo Finance
Castle Biosciences to Participate in Upcoming Investor Conferences - The Bakersfield Californian
When Can You Hear From Castle Biosciences Management? Key March Conference Dates Announced - StockTitan
Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences - GlobeNewswire
Pinning Down Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is Difficult Right Now - Simply Wall St
Castle Biosciences CFO Frank Stokes sells $214,828 in stock By Investing.com - Investing.com Australia
Castle Biosciences CFO Frank Stokes sells $214,828 in stock - Investing.com India
Wall Street Analysts See a 50.79% Upside in Castle Biosciences (CSTL): Can the Stock Really Move This High? - MSN
Castle Biosciences, Inc. (CSTL) Reports Next Week: Wall Street Expects Earnings Growth - MSN
Castle Biosciences (CSTL) Expected to Announce Earnings on Thursday - Defense World
Castle Biosciences director sells $221,636 in stock - MSN
Analysts Set Castle Biosciences, Inc. (NASDAQ:CSTL) Target Price at $40.29 - Defense World
Stephens Inc. AR Trims Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Surging Earnings Estimates Signal Upside for Castle Biosciences (CSTL) Stock - MSN
Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology ConferenceHawaii® - The Bakersfield Californian
Major Clinical Findings: Castle Bio's Breakthrough Melanoma and Skin Cancer Detection Tests Under Spotlight - StockTitan
Insider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Director Sells $221,613.39 in Stock - Armenian Reporter
Castle Biosciences director sells $221,636 in stock By Investing.com - Investing.com Australia
Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025 - BioSpace
Castle Biosciences Earnings Alert: Key Financial Results Coming Feb 27Here's How to Listen In - StockTitan
Castle Biosciences Inc Stock (CSTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):